PhaseBio, Osmotica price NASDAQ IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Oct. 17. PhaseBio trading ended flat at $5 on Oct. 18, while Osmotica was

Read the full 395 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE